Personalized Targeted Therapy for Lung Cancer
Lung cancer has long been recognized as an extremely heterogeneous disease, since its development is unique in every patient in terms of clinical characterizations, prognosis, response and tolerance to treatment. Personalized medicine refers to the use of markers to predict which patient will most l...
Main Authors: | William C.S. Cho, Wanqing Liu, Kehua Wu, Larry House |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2012-09-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/13/9/11471 |
Similar Items
-
Recent Advances and Prospect of Advanced Non-small Cell Lung Cancer Targeted
Therapy: Focus on Small Molecular Tyrosine Kinase Inhibitors
by: Guowei ZHANG, et al.
Published: (2017-04-01) -
Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets
by: Dalurzo ML, et al.
Published: (2021-09-01) -
Personalized Targeted Therapy for Lung Cancer
by: Kehua Wu, et al.
Published: (2013-08-01) -
Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine
by: Julian Pinsolle, et al.
Published: (2019-10-01) -
Biomarkers that currently effect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1 and KRAS
by: Grzegorz Janusz Korpanty, et al.
Published: (2014-08-01)